Objective: To examine differences in depressive and anxiety symptoms between boarding and non boarding high school students and their associations with physical activity (PA) patterns, so as to provide evidence to inform adolescent mental health promotion. Methods: From October to December 2024, a convenience sample of 11 782 students aged 15-18 years was recruited from 36 schools in Nanchang, Ganzhou, and Shangrao of Jiangxi Province. Depressive and anxiety symptoms and PA were assessed using the Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and International Physical Activity Questionary Short Form (IPAQ-SF). Logistic regression model was used to examine associations between PA patterns, depressive and anxiety symptoms among boarding and non boarding students. Results: The detection rates of depressive symptoms were 45.7% and 46.4% among boarding and non boarding students, respectively; for anxiety symptoms, the corresponding rates were 43.0% and 46.7%. Boarding and non boarding students differed significantly in smoking status, screen time, sleep duration, sedentary time, daily vegetable intake, and napping ( χ 2=16.74-664.17, all P <0.01). Across PA pattern groups, the detection rates of depressive and anxiety symptoms differed significantly between boarding and non boarding students ( χ 2 depression = 23.85 , χ 2 anxiety = 22.78, both P <0.01). Adjusted for confounding factors, Logistic regression analysis of high school students showed that compared with the not meeting PA recommendations, both the concentrated and regular PA pattern were associated with lower odds of depressive symptoms [ OR (95% CI )=0.83(0.70-0.98), 0.90(0.83-0.98)]; and the concentrated pattern was also associated with lower odds of anxiety symptoms [ OR (95% CI )=0.78(0.65-0.92)], and the association of anxiety symptoms in concentrated boarding students was consistent with that of the overall group [ OR (95% CI )=0.71(0.52-0.98)] (all P <0.05). Conclusions There is a correlation of different physical activity patterns with depressive and anxiety symptoms among boarding and non boarding high school students. Schools should ensure students engage in regular physical activity and work to increase overall activity volume.

Acute respimtory distress syndrome(ARDS)is an acute diffuse inflammatory lung injury caused by various internal and external lung injury factors.It has complex pathogenesis,rapid onset and high mortality,which seriously endangers human life and health.Pulmonary fibrosis is one of the important pathologic processes of ARDS occurrence and development,and it is also an important cause of death in ARDS patients.To a certain extent,the severity of pulmonary fibrosis in ARDS is determined by the dynamic balance of macrophage-fibroblast interactions.Therefore,this article aims to review the interaction mechanism of macrophage-fibroblasts in the pro-cess of ARDS pulmonary fibrosis,and provide new methods and ideas for the diagnosis and treatment of ARDS pul-monary fibrosis.

Objective To investigate the effect of baicalin(BA)regulating cyclic adenosine phosphate(cAMP)/protein kinase A(PKA)/cAMP response elemen-binding protein(CREB)pathway on skin barrier function in eczema rats.Methods SD rats were randomly divided into the control group(NC group),the model group,the low-dose BA group(BA-L group,25 mg/kg),the medium-dose BA group(BA-M group,50 mg/kg),the high-dose BA group(BA-H group,100 mg/kg),the prednisone group(PNS group,25 mg/kg),the BA-H+cAMP inhibitor(SQ22536)group(100 mg/kg+2.13 mg/kg)and the BA-H+PKA inhibitor(H-89)group(100 mg/kg+5 mg/kg),12 animals in each group.Except for the NC group,eczema rat model was constructed in the other groups.Two days after successful modeling,drug administration was performed in groups.Changes of eczema area and severity index(EASI)score,transcutaneous water loss(TEWL)and cuticle water content(WCSC)were detected.Enzyme-linked immunosorbent assay(ELISA)was used to detect levels of immunoglobulin E(IgE),interferon-γ(IFN-γ)and interleukin-4(IL-4)in rat serum and the expression of cAMP protein in rat back lesions.HE staining was used to detect pathological changes of skin lesions on the back of rats.Western blot assay was used to detect aquaporin 3(AQP3),cathelicidin related antimicrobial peptide(CRAMP),p-PKA,p-CREB protein expression in rat back lesions.Results Compared with the NC group,rats had serious pathological lesions on the back of the tested area,increased EASI score,TEWL,IgE and IL-4 levels,and decreased WCSC,IFN-γ,AQP3,CRAMP,cAMP,p-PKA and p-CREB protein levels in the model group(P<0.05).Compared with the model group,pathological lesion of the tested area in the back of rats was relieved,and EASI score,TEWL,IgE and IL-4 levels were decreased,WCSC,IFN-γ levels,AQP3,CRAMP,cAMP,p-PKA and p-CREB protein were increased in the BA-L group,the BA-M group,the BA-H group and the PNS group(P＜0.05).Changes of above indexes in the BA-L group,the BA-M group,the BA-H group were dose-dependent.SQ22536 or H-89 attenuated the improvement effect of high dose BA on skin barrier function in eczema rats.Conclusion BA may improve skin barrier function in eczema rats by activating cAMP/PKA/CREB signaling pathway.

Weight loss is a prevalent non-motor symptom of Parkinson's disease(PD), often appearing several years before motor symptoms and continuing throughout the course of the disease.The cause of weight loss in PD may be linked to an imbalance in energy and neuroendocrine function.Ghrelin and leptin are thought to be significant factors in the weight loss experienced by those with PD.Obstructive sleep apnea hypopnea syndrome may independently increase the risk of PD and significantly impact the cognitive and motor functions, as well as other non-motor symptoms, of PD patients.Research has shown that a hypoxic environment can enhance the expression and aggregation of the pathogenic protein α-synuclein.This suggests that hypoxic stress and intermittent hypoxia may be contributing factors to the development of PD.This article examines the correlation between weight loss in patients with Parkinson's disease and the hormones ghrelin and leptin, as well as the impact of a hypoxic environment on these hormones.

Objective To identify the independent risk factors of cognitive impairment(CI)in patients with cerebral small vessel disease(CSVD)and construct a clinical prediction model.Methods Patients with CSVD who were hospitalized in the First Affiliated Hospital of Xi'an Jiaotong University from January 1,2017 to December 31,2022 were retrospectively enrolled,and were divided into a group with cognitive impairment(CSVD-CI group,n=83)and a group without cognitive impairment(CSVD-NCI group,n=164)according to the mini-mental state examination(MMSE).The influence factors of cognitive impairment were screened by logistic regression.The clinical prediction model of the nomogram was further developed based on the screened factors,and the efficacy of the model was tested.Results Compared with patients in the CSVD-NCI group,patients in the CSVD-CI group had higher neutrophil/lymphocyte ratio(NLR)(3.03±2.56 vs 2.33±1.34)and(1.58±0.27 vs 1.49±0.28),and a lower estimated glomerular filtration rate[eGFR:88.59±16.59 ml/(min·1.73m2)vs 94.02±12.45 ml/(min·1.73m2)],with significant differences(t=2.282,2.426,2.689,all P＜0.05).Compared with patients in the CSVD-NCI group,patients in the CSVD-CI group had lower proportion of males(43.4％vs 67.7％)and level of education(2.13±1.50 vs 2.86),and the differences were significant(x2=13.516,t=4.283,all P＜0.05).NLR(OR:1.20,95％CI:1.01～1.43),sex(OR:0.43,95％CI:0.24～0.79),eGFR(OR:0.97,95％CI:0.95～0.99)and education degree(OR:0.72,95％CI:0.57～0.91)were the impact factors for cognitive impairment in CSVD patients.The nomogram prediction model based on these four factors had good efficacy in predicting cognitive impairment(AUC=0.704,95％CI:0.633～0.766).Conclusion The nomogram constructed in this study has moderate accuracy and clinical utility in predicting the occurrence of cognitive impairment in CSVD patients.

Parkinson's disease(PD)has a complex etiology and an unclear mechanism, involving genetic, environmental, and aging factors.Identifying common elements is crucial for pinpointing intervention targets.Hypoxia, which is prevalent in both natural environments and various disease states, is closely associated with the etiology of PD.It may enhance the expression and aggregation of the pathogenic protein α-synuclein, thereby influencing the onset and progression of PD through multiple pathways.Hypoxia-induced factor-1α(HIF-1α)and nuclear factor E2 related factor 2(Nrf2)are signaling molecules that are intimately linked to oxygen regulation and play a significant role in modulating oxidative stress.The underlying mechanisms may involve reducing neuronal apoptosis, mitigating inflammatory responses, and alleviating oxidative stress.Research indicates that the activation of HIF-1α and Nrf2-related signaling pathways can provide protection to dopaminergic neurons in the substantia nigra.Consequently, this review aims to summarize the relationship between PD and HIF-1α, Nrf2, along with the implications of hypoxic environments.

Objective: First-line bevacizumab plus carboplatin and paclitaxel (CP) is approved for stage III/IV ovarian cancer treatment following initial surgical resection, based on global phase III GOG-0218 and ICON7 trials. This study evaluated the efficacy and safety of bevacizumab + CP as first-line ovarian cancer therapy in Chinese patients. Methods: Patients with newly diagnosed, International Federation of Gynecology and Obstetrics (FIGO) stage III/IV epithelial ovarian, fallopian tube, or primary peritoneal cancer post-primary surgery were randomized 1:1 to receive 6 cycles of CP with bevacizumab/ placebo, followed by bevacizumab/placebo maintenance until unacceptable toxicity or disease progression. Primary endpoint was investigator-assessed progression-free survival (PFS). Stratification factors were FIGO stage and debulking status (stage III optimally debulked vs stage III suboptimally debulked vs stage IV) and Eastern Cooperative Oncology Group performance status (0 vs 1 or 2). Results: Of randomized patients, 51 received bevacizumab + CP and 49 received placebo + CP. Median PFS was 22.6 months with bevacizumab + CP (95% confidence interval [CI]=18.6, not estimable) and 12.3 months (95% CI=9.5, 15.0) with placebo + CP (stratified hazard ratio=0.30; 95% CI=0.17, 0.53). Treatment-related grade 3/4 adverse events occurred in 46 of 49 (94%) patients receiving bevacizumab + CP, and 34 of 50 (68%) receiving placebo + CP. Conclusion Bevacizumab + CP showed clinically meaningful improvement in PFS vs placebo + CP, consistent with GOG-0218 results. Safety data were aligned with the known bevacizumab safety profile. These results support first-line bevacizumab + CP therapy in Chinese patients with ovarian cancer.

Objective: First-line bevacizumab plus carboplatin and paclitaxel (CP) is approved for stage III/IV ovarian cancer treatment following initial surgical resection, based on global phase III GOG-0218 and ICON7 trials. This study evaluated the efficacy and safety of bevacizumab + CP as first-line ovarian cancer therapy in Chinese patients. Methods: Patients with newly diagnosed, International Federation of Gynecology and Obstetrics (FIGO) stage III/IV epithelial ovarian, fallopian tube, or primary peritoneal cancer post-primary surgery were randomized 1:1 to receive 6 cycles of CP with bevacizumab/ placebo, followed by bevacizumab/placebo maintenance until unacceptable toxicity or disease progression. Primary endpoint was investigator-assessed progression-free survival (PFS). Stratification factors were FIGO stage and debulking status (stage III optimally debulked vs stage III suboptimally debulked vs stage IV) and Eastern Cooperative Oncology Group performance status (0 vs 1 or 2). Results: Of randomized patients, 51 received bevacizumab + CP and 49 received placebo + CP. Median PFS was 22.6 months with bevacizumab + CP (95% confidence interval [CI]=18.6, not estimable) and 12.3 months (95% CI=9.5, 15.0) with placebo + CP (stratified hazard ratio=0.30; 95% CI=0.17, 0.53). Treatment-related grade 3/4 adverse events occurred in 46 of 49 (94%) patients receiving bevacizumab + CP, and 34 of 50 (68%) receiving placebo + CP. Conclusion Bevacizumab + CP showed clinically meaningful improvement in PFS vs placebo + CP, consistent with GOG-0218 results. Safety data were aligned with the known bevacizumab safety profile. These results support first-line bevacizumab + CP therapy in Chinese patients with ovarian cancer.

Objective: First-line bevacizumab plus carboplatin and paclitaxel (CP) is approved for stage III/IV ovarian cancer treatment following initial surgical resection, based on global phase III GOG-0218 and ICON7 trials. This study evaluated the efficacy and safety of bevacizumab + CP as first-line ovarian cancer therapy in Chinese patients. Methods: Patients with newly diagnosed, International Federation of Gynecology and Obstetrics (FIGO) stage III/IV epithelial ovarian, fallopian tube, or primary peritoneal cancer post-primary surgery were randomized 1:1 to receive 6 cycles of CP with bevacizumab/ placebo, followed by bevacizumab/placebo maintenance until unacceptable toxicity or disease progression. Primary endpoint was investigator-assessed progression-free survival (PFS). Stratification factors were FIGO stage and debulking status (stage III optimally debulked vs stage III suboptimally debulked vs stage IV) and Eastern Cooperative Oncology Group performance status (0 vs 1 or 2). Results: Of randomized patients, 51 received bevacizumab + CP and 49 received placebo + CP. Median PFS was 22.6 months with bevacizumab + CP (95% confidence interval [CI]=18.6, not estimable) and 12.3 months (95% CI=9.5, 15.0) with placebo + CP (stratified hazard ratio=0.30; 95% CI=0.17, 0.53). Treatment-related grade 3/4 adverse events occurred in 46 of 49 (94%) patients receiving bevacizumab + CP, and 34 of 50 (68%) receiving placebo + CP. Conclusion Bevacizumab + CP showed clinically meaningful improvement in PFS vs placebo + CP, consistent with GOG-0218 results. Safety data were aligned with the known bevacizumab safety profile. These results support first-line bevacizumab + CP therapy in Chinese patients with ovarian cancer.

Objective To investigate the effect of Shenqi Yizhi Granules on brain structure and function in prodromal Alzheimer disease（pAD） under hypoxic conditions based on MRI. Methods A total of 77 female Han Chinese patients， aged 50‒85 years， who had at least 6 years of education and long-term residence in Qinghai region and met the inclusion criteria for pAD were enrolled as subjects. They were randomly divided into drug group （39 patients receiving Shenqi Yizhi Granules） and control group （38 patients receiving placebo） for 24 weeks of clinical observation. Related data were collected from all subjects， including clinical information， cognitive and neuropsychological assessments， diffusion tensor imaging （DTI） data， and rs-fMRI data. Results Cognitive and neuropsychological assessments showed that after treatment， the drug group had significant increases in MoCA， AVTL， SDMT， and CFT-copy scores and significant reductions in ADAS-cog and GDS scores（P<0.05）， while the control group had a significantly increase in ADAS-cog score （P<0.001）； compared with the control group after treatment， the drug group had significantly higher MoCA and AVTL scores （P<0.05） and a significantly lower ADAS-cog score （P<0.01）. DTI results showed that the drug group had significant increases in axial diffusivity （AD） values of multiple brain regions after treatment （P<0.05）. The results of rs-fMRI showed that after treatment， the drug group had significant increases in the amplitude of low-frequency fluctuation （ALFF） in the right temporal middle gyrus， the triangular part of the inferior frontal gyrus， and the medial cingulate gyrus and paracingulate gyrus and significant reductions in ALFF in the left cerebellar hemisphere Crus1 lobule， superior occipital gyrus， and supramarginal gyrus， and compared with the control group， the drug group had a significant increase in ALFF in the right dorsolateral superior frontal gyrus （P<0.05）. After treatment， the drug group had significant increases in the regional homogeneity （ReHo） values of the left triangular part of the inferior frontal gyrus and the inferior occipital gyrus and a significant reduction in the ReHo value of the left cerebellar hemisphere Crus1 lobule （P<0.05）， and compared with the control group， the drug group had a significant increase in the ReHo value of the left inferior parietal gyrus（P<0.05）. Conclusion Shenqi Yizhi Granules can effectively improve overall cognition and the function of multiple cognitive domains in pAD patients living in plateau regions by modulating the microstructure of white matter and spontaneous neuronal activity in cognitive-related brain regions.